Data from the HER2CLIMB-05 study indicate that adding another drug, tucatinib (Tukysa), to the maintenance therapy phase for women with advanced HER2-positive (HER2+) breast cancer can significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback